New FM station coming to Westfield
WESTFIELD — A new FM radio station is coming to Westfield. Westfield programming at WSKB is moving to WSFD-LP at 107.5 FM at the beginning of July.
Westfield Media Specialist Peter Cowles said in late 2023, the Federal Communications Commission opened a one-month filing period for a low power FM station for the first time in a decade. Cowles received permission from Mayor Mike McCabe to apply as a public safety entity and jumped on it, he said. Westfield was one of two applicants out of eight that were selected.
Cowles said Westfield had an original partnership with the Westfield State University student station WSKB, but the students at the university have been wanting it back.
WSFD will be city-owned, with students at Westfield Technical Academy, where the studio is located, as the primary technicians on the station. He said it will also be open to the community at large for programming. The city is licensed with all three businesses, ASCAP, BMI and CESAC to play music. The station will also broadcast all emergency alerts in the city.
On May 12, the Finance committee voted to recommend a transfer of $20,222 from the PEG Undesignated fiscal year 2025 account to the PEG Additional/Capital Equipment Account to purchase equipment for the station to finish off a 300 watt transmitter chain for the emergency Services alarm system. Cowles said they already have the computer, audio board and mics.
Information Technology Manager Lenore Bernashe was able to get additional savings from Westfield Gas & Electric, who will increase the 80-foot tower located at the Water Department by adding 20 feet. Cowles said there are public safety receivers on it now that were put in six to seven years ago, and have a good range.
Cowles said the 100-watt LPV station will reach Springfield and Northampton. 'That's why this site was perfect, and it's backed up on a mountain in Granby,' he said, adding that they will transition over on July 1 when the work is done.
The new station is only one of the changes going on in the studio.
On April 14, the City Council approved an expenditure of $296,915 from the PEG Undesignated Account, which is an enterprise fund, for a Mobile Sprinter Van. The van will cost $80,000 with $217,000 for customization and equipment including a 40-foot mast and camera, and will be used as a mobile television unit, able to cover city meetings and sporting events, and also able to be used as a short-term mobile command post as needed by the Police Department.
Also in the works is a Chapter 74 certification for digital media, formerly called television and radio, as another career technical education program under graphic arts at WTA. 'I think it's a huge advantage for the program,' Cowles said. He said students will be able to run the radio programming and staff the vehicle, with a lot of opportunities to use the equipment and to train.
He said they are presently rewriting the frameworks for the program. The school will be meeting with the Department of Elementary and Secondary Education in the next two weeks for the final word on Chapter 74, and have already toured the television station at WTA and made suggestions. Cowles said all in all they were impressed by the setup at the school. 'I can't believe what you did in such a small space — that's a quote from DESE,' he said.
He said next year when the students return to school, the radio station WSFD will be up and running, and the mobile production unit will be on its way. 'A lot of changes happening all at once,' Cowles said.
Read the original article on MassLive.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Orlando Luxury Transportation Expands Fleet to Meet Rising Demand for Group Services
Orlando Luxury Transportation adds a Sprinter Limo and Mini Bus to enhance its group service offerings across Central Florida Windermere, Florida--(Newsfile Corp. - June 4, 2025) - Orlando Luxury Transportation, a leader in executive and private chauffeur services since 2010, has announced the expansion of its fleet with two new vehicles: a luxury Sprinter Limo and a modern Mini Bus. These additions are designed to meet the growing demand for reliable group mobility throughout Central Florida, while maintaining the sophistication that defines the brand. Orlando Luxury Transportation Expands Fleet to Meet Rising Demand for Group Services To view an enhanced version of this graphic, please visit: Both vehicles were selected with passenger satisfaction in mind. The Sprinter Limo includes amenities that elevate every group outing. Passengers can enjoy a surround sound music system and Bluetooth connectivity, allowing for custom playlists and effortless syncing from personal devices. The interior lighting includes dynamic disco lights that enhance celebratory moods, while multiple large TV screens add a layer of visual entertainment. A built-in minibar, champagne glass holders, and a spacious ice bin all contribute to a refined atmosphere, making them ideal for small parties, corporate events, and special celebrations. Complementing the Sprinter, the newly acquired Mini Bus is suited for mid-size group transportation. It features leather seating configured for relaxed conversation, tinted windows to ensure privacy, and a sound system engineered for clarity. The inclusion of multiple LCD screens offers convenient media access during longer rides. With its spacious interior and entertainment capabilities, the Mini Bus meets the needs of conference shuttles, team transfers, and upscale group engagements. "This fleet expansion reflects the feedback from clients seeking private options that combine sophistication with group capacity," said Juan Moya, owner of Orlando Luxury Transportation. "Each vehicle was selected to enhance comfort, entertainment, and the overall experience for our passengers." Orlando Luxury Transportation adds a Sprinter Limo and Mini Bus to enhance its group service offerings To view an enhanced version of this graphic, please visit: The announcement comes amid a rising demand for group transportation in Orlando and beyond, particularly for coordinated event transfers, family gatherings, and corporate travel. The company's investment positions it to meet these demands without compromising the elegance and dependability expected by returning and new clientele. As a well-established operator in the region, Orlando Luxury Transportation has consistently prioritized personalized attention and timely service. Its reputation is built on reliability and care, qualities increasingly important in today's group mobility landscape. With these vehicle additions, the company strengthens its position as a reliable partner for Orlando car service with an emphasis on group convenience and comfort. The Sprinter Limo and Mini Bus are now available for immediate booking. For more details, visit Orlando Luxury Transportation's Fleet Page or contact the reservation team via their booking portal. About Orlando Luxury Transportation: Orlando Luxury Transportation is a Florida-based company providing high-comfort chauffeured services for private individuals, families, and professional groups. Operating since 2010, the company offers round-the-clock availability, flexible scheduling, and a fleet that meets the demands of both individual travelers and larger parties. This latest fleet expansion highlights the company's commitment to consistent advancement and client-focused solutions. info@ Media Contact: To view an enhanced version of this graphic, please visit: Company Name: Orlando Luxury Transportation Contact Person: Juan Moya Phone: (888) 744-3419 Address: 6026 Golden Dewdrop Trail City: Windermere State: FL Postal Code: Country: 34786 Website: To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ('Cook MyoSite') to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, 'We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.' Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella's Board of Directors, added, 'Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella's clinical progress.' About Cook MyoSite Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection and expansion of human skeletal muscle cells for the treatment of various disorders. In addition to operating several regulated clinical studies, Cook MyoSite provides a range of custom services, including modified cell samples to contract manufacturing arrangements, procurement and processing of muscle cells from specific donor populations, custom media formulations, CMO/CDMO arrangements and QC analytical testing and assay development. Learn more about Cook MyoSite at About Lipella Pharmaceuticals Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking StatementsThis press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, including the statistically significant safety and efficacy data presented above for LP-310, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the current clinical trial for LP-310, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals PCG AdvisoryJeff Ramsonjramson@


Business Upturn
4 days ago
- Business Upturn
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ('Cook MyoSite') to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, 'We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.' Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella's Board of Directors, added, 'Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella's clinical progress.' About Cook MyoSite Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection and expansion of human skeletal muscle cells for the treatment of various disorders. In addition to operating several regulated clinical studies, Cook MyoSite provides a range of custom services, including modified cell samples to contract manufacturing arrangements, procurement and processing of muscle cells from specific donor populations, custom media formulations, CMO/CDMO arrangements and QC analytical testing and assay development. Learn more about Cook MyoSite at . About Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking Statements This press release includes certain 'forward-looking statements.' All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, including the statistically significant safety and efficacy data presented above for LP-310, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as 'may,' 'will,' 'could,' 'continue,' 'would,' 'should,' 'potential,' 'target,' 'goal,' 'anticipates,' 'intends,' 'plans,' 'seeks,' 'believes,' 'estimates,' 'predicts,' 'expects,' 'projects' and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the current clinical trial for LP-310, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals Inc. [email protected] 1-412-894-1853